Eli Lilly and Company » Facts at a Glance

Skip to: Major Marketed Products, Employees, Financials, Research and Development, Staff, Cost of New Pharmaceuticals, Awards & Recognition

A heritage more than 130 years strong: company founded on May 10, 1876
Headquarters located in Indianapolis, Indiana, U.S.A.
Approximately 40,788 employees worldwide
Approximately 7,474 employees engaged in research and development
Clinical research conducted in more than 50 countries
Research and development facilities located in 8 countries
Manufacturing plants located in 13 countries
Products marketed in 143 countries

Major Marketed Products

(Dates indicate the year of first global launch. For complete prescribing information, please visit product website)

2009: Adcirca™ (tadalafil) for pulmonary arterial hypertension (U.S.)(outlicensed for US sales and marketing to United Therapeutics)
2009: Efient™ (prasugrel) for the prevention of atherothrombotic events in patients with ACS undergoing percutaneous coronary intervention (Europe)(in collaboration with Daiichi Sankyo Company, Ltd.)
Effient™ (prasugrel) for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who to be managed with an artery-opening procedure known as percutaneous coronary intervention (PCI). (U.S.)(in collaboration with Daiichi Sankyo, Inc.)
2005: Byetta® (exenatide) for type 2 diabetes
for use in combination with a thiazolidinedione (2007)
(in collaboration with Amylin Pharmaceuticals, Inc.)
2004: Alimta® (pemetrexed) for malignant pleural mesothelioma
for second-line treatment of non-squamous non-small-cell lung cancer (NSCLC) (2004)
for first-line treatment of non-squamous NSCLC (2008)
2004: Cymbalta® (duloxetine) for major depressive disorder
for diabetic peripheral neuropathic pain (2004)
for generalized anxiety disorder (2007)
for the maintenance treatment of major depressive disorder (2007)
for fibromyalgia (2008)
(in collaboration with Quintiles Transnational Corp. in the U.S., Shionogi & Co. Ltd. in Japan, and with Boehringer Ingelheim elsewhere in the world)
2004: Erbitux® (cetuximab) for later-stage EGFR-expressing metastatic colorectal cancer
for locally or regionally advanced squamous cell head and neck cancer (2006)
for later-stage recurrent or metastatic squamous cell head and neck cancer (2006)
(in collaboration with Bristol-Myers Squibb Co. in North America and Japan, and Merck KGaA outside of North America and in Japan)
2004: Symbyax® (olanzapine/fluoxetine) for bipolar depression
for acute treatment of adult patients with major depressive disorder who have not responded to two separate trials of different antidepressants of adequate dose and duration in their current episode (2009)
2004: Yentreve® (duloxetine) for stress urinary incontinence (outside the U.S.)
2003: Cialis® (tadalafil) for erectile dysfunction
for once daily use (2007)
2003: Strattera® (atomoxetine) for attention-deficit hyperactivity disorder (ADHD) in children, adolescents, and adults
for maintenance treatment of ADHD in children and adolescents (2008)
2002: Forteo® (teriparatide) for treatment of men and postmenopausal women with osteoporosis who are at high risk for a fracture
for the treatment of glucocorticoid-induced osteoporosis (2008; Europe)
2001: Xigris® (drotrecogin alfa [activated]) for severe sepsis in adult patients at high risk of death
1999: Actos® (pioglitazone) for type 2 diabetes (in collaboration with Takeda outside the U.S.)
1998: Evista® (raloxifene) for prevention of osteoporosis in postmenopausal women for treatment of osteoporosis in postmenopausal women (1999)
for reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis (2007)
for reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer (2007)
(in collaboration with Chugai Pharmaceutical Co., Ltd. in Japan)
1996: Zyprexa® (olanzapine) for schizophrenia
for acute bipolar mania (2000)
Zyprexa® Zydis® tablet (2000)
for schizophrenia maintenance (2001)
as combination therapy with lithium or valproate for acute bipolar mania (2002)
for bipolar maintenance (2003)
Rapid-acting IntraMuscular formulation (2004)
Zyprexa® granules (2004; launched in Japan only)
Zypadhera™ for maintenance treatment of adult patients with schizophrenia sufficiently stabilized during acute treatment with oral olanzapine (2009)
1996: Humalog® (lispro recombinant insulin) for treatment of type 1 and type 2 diabetes
Humalog® Mix 75/25 (1999)
Humalog® Mix 50/50 (1999)
1995: Gemzar® (gemcitabine) for first-line non-small cell lung cancer
for pancreatic cancer (1996)
for bladder cancer (1999; outside the U.S.)
for metastatic breast cancer (2003)
for recurrent ovarian cancer (2004)
for biliary tract cancer (2006; Japan)
1995: ReoPro® (abiciximab) for prevention of cardiac ischemic complications in patients undergoing coronary intervention, such as angioplasty
for unstable angina associated with stent procedure (1997)
(in collaboration with Centocor, except in Japan)
1987: Humatrope® (somatropin recombinant) for growth failure caused by pediatric growth hormone deficiency
for replacement therapy for adult growth hormone deficiency (1995)
for short stature caused by Turner syndrome (1997)
for idiopathic short stature (2003)
1983: Humulin® (human insulin recombinant) for type 1 and type 2 diabetes

Employees (as of 09/30/09)

Indianapolis : 11,895
Indiana (excluding Indianapolis) : 1,693
U.S. (excluding Indiana) : 6,836
Outside U.S. : 20,364
Worldwide total : 40,788

Financials - 2008

(dollars in millions, except per-share data)

Net sales: $20,378.0
Net income(loss) as reported: $(2,071.9)
Earnings(loss) per share as reported: $(1.89)
Dividends paid per share: $1.88
Capital expenditures: $947.2

Research and Development

2008 Expenditures

$3,841 million/year
$320.1 million/month
$73.87 million/week
$15.12 million/workday

Increase from previous year: 10 percent
R&D as a percentage of sales: 19 percent

Staff

Employees engaged in Lilly R&D activities: 7,474
Percent of total work force: 18.5 percent

Cost of New Pharmaceuticals

Average cost to discover and develop a new drug: $800 million to $1.2 billion
Average length of time from discovery to patient: 10 to 15 years

Awards & Recognition

Receiving recognition for a job well done is always a special honor. It's an affirmation that we are sustaining Lilly's heritage of service and commitment to helping others. Making a difference in people's lives is often reward enough. Nevertheless, at Lilly we are proud of the awards we have received for the accomplishments and contributions we've made in our industry and to society overall.

Fortune Magazine "Global Top Companies for Leaders"
Points of Light Institute “Award of Excellence Corporate Engagement”
U.S. Department of the Interior “Take Pride in America”
United Way Spirit of America® Award
Forbes.com “Most Generous U.S. Companies”
Human Rights Campaign Foundation “Corporate Equity Index – 100 Ranking”
Institutional Investor “Top Shareholder-Friendly Companies”
Med Ad News “Most Admired Global Companies”
Science magazine “Best Companies for Scientists”
U.S. Small Business Administration “Outstanding Rating for Supplier Diversity Initiatives”
United Way of America “Summit Award for Corporate Philanthropy, Community Investment and Community Impact”
Working Mother Magazine “100 Best Companies for Working Mothers”